Trial · NCT04961528
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of patients with complete or partial resolution of hemoptysis without the use of any interventional procedure. | 3 days | Efficacy of inhaled tranexamic acid and inhaled terlipressin versus placebo (normal saline) in immediate control of mild to severe hemoptysis within the first 3 days of hospitalization. A complete resolution of hemoptysis is defined by absence of recurrence within 3 days; partial resolution is defined as hemoptysis recurrence \< 50 ml within the first 3 days |
| Secondary | Rate of complete resolution of hemoptysis within 3 days, as previously defined | 3 days | Complete resolution of hemoptysis, as previously defined |
| Secondary | Rate of partial resolution of hemoptysis defined as recurrence < 50 ml | 3 days | Partial resolution of hemoptysis, as previously defined |
| Secondary | Rate of patients with total volume of hemoptysis < 200 ml | 3 days | Total volume of hemoptysis \< 200 ml |
| Secondary | Rate of patients who need an endovascular treatment (bronchial arterial endovascular embolization) | 3 days | Need of invasive procedure such as bronchial arterial endovascular embolization |
| Secondary | Time between hospital admission and bronchial arterial endovascular embolization | 3 days | Time between hospital admission and endovascular treatment |
| Secondary | Rate of patients who need a mechanical ventilation | 3 days | Need of invasive procedure such as mechanical ventilation, |
| Secondary | Rate of specific adverse events | 3 days | Specific Adverse Events (AE) : acute myocardial ischemia, symptomatic venous thromboembolism, hyponatremia (\<130 mmol/L), bronchospasm (defined by the need of short-acting bronchodilatator). |
| Secondary | Rate of in-hospital mortality | 30 days | |
| Secondary | Rate of patients with hemoptysis recurrence | 30 days | |
| Secondary | Death rate | 30 days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04961528/registered